Pharmacovigilance Market: Biologics Surveillance Trends, Advanced Therapy Monitoring, & Growth Outlook

According to IMARC Group's latest research publication, the global pharmacovigilance market size was valued at USD 8.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 16.3 Billion by 2034, exhibiting a growth rate of 7.5% during 2026-2034.

How AI is Reshaping the Future of Pharmacovigilance Market

• Automated Case Processing and Intelligent Data Extraction Natural language processing transforms how safety teams handle adverse event reports, automatically extracting critical information from emails, medical records, and call center transcripts.

• Predictive Signal Detection and Real-Time Risk Assessment Advanced analytics platforms analyze thousands of safety reports simultaneously, identifying emerging patterns and potential drug-safety signals before they escalate into public health concerns.

• Enhanced Regulatory Compliance Through Intelligent Automation AI-powered platforms streamline the creation of Individual Case Safety Reports and periodic safety updates, ensuring submissions meet evolving regulatory standards across different markets.

Get In-Depth 2026 Industry Insights & Projections

Pharmacovigilance Industry Overview

Regulatory frameworks are driving unprecedented transformation as the FDA and EMA jointly established ten guiding principles for responsible AI use across the medicines lifecycle, emphasizing human-centric approaches and transparent model validation.

Pharmacovigilance Market Trends & Drivers

The pharmaceutical industry's shift toward complex biologics and personalized medicine is fundamentally changing safety monitoring requirements, creating sustained demand for sophisticated pharmacovigilance systems. Over 22,000 new clinical trials launched recently, many featuring adaptive protocols and decentralized elements that generate safety data from diverse patient populations across multiple geographies.

Rising prevalence of chronic diseases combined with widespread polypharmacy is intensifying adverse drug reaction monitoring needs across healthcare systems worldwide. Studies show that 44% to 58% of adults aged 65 and older take at least five medications simultaneously, with uncoordinated prescribing amplifying risks of dangerous drug interactions.

Regulatory agencies are implementing stricter post-market surveillance requirements as more medicines receive accelerated approvals based on limited pre-authorization data. The FDA's Drug Safety Technology Meetings program provides forums where pharmacovigilance vendors and software developers discuss emerging AI technologies with regulatory staff, establishing clear expectations for algorithmic transparency and validation.

Leading Companies Operating in the Global Pharmacovigilance Industry

• Accenture plc
• ArisGlobal LLC
• BioClinica Inc. (Cinven Partners LLP)
• Capgemini
• Cognizant
• International Business Machines Corporation
• ICON plc.
• IQVIA Inc.
• ITClinical
• Parexel International Corporation
• Wipro Limited

Pharmacovigilance Market Report Segmentation

By Service Provider:

• In-house
• Contract Outsourcing

Contract outsourcing represents the largest segment at 61.2% market share owing to cost efficiency and access to specialized regulatory expertise.

By Product Life Cycle:

• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Phase IV dominates with 76.5% market share as post-marketing surveillance and long-term safety monitoring remain critical regulatory requirements.

By Type:

• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

Spontaneous reporting leads with 31.9% market share due to its widespread adoption and regulatory acceptance across global markets.

By Process Flow:

• Case Data Management
• Case Logging
• Case Data Analysis
• Medical Reviewing and Reporting
• Signal Detection
• Adverse Event Logging
• Adverse Event Analysis
• Adverse Event Review and Reporting
• Risk Management System
• Risk Evaluation System
• Risk Mitigation System

Signal detection holds the largest segment at 38.2% as early identification of safety concerns becomes increasingly critical.

By Therapeutic Area:

• Oncology
• Neurology
• Cardiology
• Respiratory Systems
• Others

Oncology commands 27.8% market share driven by complex cancer therapies requiring intensive safety monitoring throughout treatment.

By End Use:

• Pharmaceutical Companies
• Biotechnology Companies
• Medical Device Companies
• Others

Pharmaceutical companies represent 44.2% of the market due to their extensive regulatory responsibilities and compliance requirements.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America dominates with 33.7% market share driven by advanced healthcare infrastructure, stringent FDA regulations, and significant pharmaceutical industry presence.

Recent News and Developments in Pharmacovigilance Market

• April 2025: ELIQUENT Life Sciences acquired Truliant Consulting, a leading pharmacovigilance, risk management, and regulatory compliance firm, enhancing its end-to-end product lifecycle support.
• March 2025: Tech Mahindra and NVIDIA collaborated to develop an agentic AI-powered pharmacovigilance solution that enhances drug safety management by automating and optimizing workflows.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.